-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Supplementary Chinese patent medicines are becoming the main object of local medical insuran.
On July 12, the Beijing Medical Insurance Bureau issued a notice on "The City's Third Batch of Drug Varieties from the National Medical Insurance Drug List", which removed 141 drugs from the Beijing Medical Insurance List, half of which were proprietary Chinese medicines, reaching 7 o.
It is reported that the varieties withdrawn this time are part of the supplementary clearance of local medical insurance across the count.
On June 30, Guangxi released a list of drugs to be withdrawn and supplement.
There are 168 drugs on the list, of which 155 are proprietary Chinese medicin.
In May, Jiangxi Province announced the "Notice on Transferring the Retained Chinese Patent Medicines from the Medical Insurance Payment Scope during the Transition Period", announcing that 43 Chinese patent medicines that had not been included in the national medical insurance were transferred out of the medical insuran.
In addition to the above-mentioned provinces and cities, Fujian, Anhui, Zhejiang, Shanghai, Chongqing, Sichuan and many other places have also released "digestion" lists, and a large number of proprietary Chinese medicines will withdraw from the medical insurance mark.
According to the "Opinions on Establishing a Medical Insurance Benefit List Management System (Draft for Comments)" issued by the National Medical Insurance Bureau in July 2019, the three-year removal and supplementation actions have been carried out in various regio.
Accelerate withdrawal from medical insurance, among which traditional Chinese medicine injections have become the focus of accelerated clearan.
It is foreseeable that the days of traditional Chinese medicine enterprises are becoming more and more difficult, and their survival is facing great challeng.
So, where should Chinese medicine companies go in the future? Regarding the future trend of the traditional Chinese medicine industry, Southwest Securities once analyzed and pointed out that the policies of the traditional Chinese medicine industry are constantly changing, and the immune properties of traditional Chinese medicine consumer products are highlight.
In terms of policy, in fact, the policy support for the TCM industry in promoting TCM innovation, TCM internationalization, TCM quality control and TCM medical services is increasi.
Since 2021, including "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics", "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Chinese and Western Medicine", and "Implementation Plan for the Dissemination of Traditional Chinese Medicine Culture" (2021-2025) " and many other favorable policies have been introduced to support the innovation and development of the traditional Chinese medicine indust.
In 2021, a total of 33 Class 1 new drugs will be approved for marketing, including 6 proprietary Chinese medicin.
The local centralized procurement of proprietary Chinese medicines is mainly based on traditional Chinese medicine injections, and traditional Chinese medicine consumer goods have consumption attribut.
Since 2021, the upstream Chinese medicinal materials have ushered in a price increase, and the downstream of traditional Chinese medicine consumer goods with brand effects has gradually completed the price increase due to technical barrie.
The market is doing we.
In addition, traditional Chinese medicine consumer products are mainly in the out-of-hospital market, and the centralized procurement in the in-hospital market has less impact, so it is relatively immune to medical insuran.
The industry believes that there is a big opportunity for the development of traditional Chinese medicine consumer goods, and the future performance is expected to explo.
In addition, compared with proprietary Chinese medicines, the industry generally believes that Chinese herbal decoction pieces and formula granules are less pressured by medical insurance to control costs and have growth potenti.
Among them, under the introduction of national standards for formula granules, the industry is gradually moving towards standardized operation, and the increase in cost will bring about an increase in terminal pric.
In recent years, the market size of traditional Chinese medicine formula granules has grown rapidly, from 15 billion yuan in 2015 to about 30 billion yuan in 202 The industry expects that with the removal of restrictions on the use of formula granules, the market size of traditional Chinese medicine formula granules will still rema.
Rapid grow.
In recent years, Chinese herbal decoction pieces have also maintained a growth trend against the background of consumption leve.
In 2021, Chinese herbal medicine decoction pieces will have a high growth trend, with a profit growth rate of 10
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
On July 12, the Beijing Medical Insurance Bureau issued a notice on "The City's Third Batch of Drug Varieties from the National Medical Insurance Drug List", which removed 141 drugs from the Beijing Medical Insurance List, half of which were proprietary Chinese medicines, reaching 7 o.
It is reported that the varieties withdrawn this time are part of the supplementary clearance of local medical insurance across the count.
On June 30, Guangxi released a list of drugs to be withdrawn and supplement.
There are 168 drugs on the list, of which 155 are proprietary Chinese medicin.
In May, Jiangxi Province announced the "Notice on Transferring the Retained Chinese Patent Medicines from the Medical Insurance Payment Scope during the Transition Period", announcing that 43 Chinese patent medicines that had not been included in the national medical insurance were transferred out of the medical insuran.
In addition to the above-mentioned provinces and cities, Fujian, Anhui, Zhejiang, Shanghai, Chongqing, Sichuan and many other places have also released "digestion" lists, and a large number of proprietary Chinese medicines will withdraw from the medical insurance mark.
According to the "Opinions on Establishing a Medical Insurance Benefit List Management System (Draft for Comments)" issued by the National Medical Insurance Bureau in July 2019, the three-year removal and supplementation actions have been carried out in various regio.
Accelerate withdrawal from medical insurance, among which traditional Chinese medicine injections have become the focus of accelerated clearan.
It is foreseeable that the days of traditional Chinese medicine enterprises are becoming more and more difficult, and their survival is facing great challeng.
So, where should Chinese medicine companies go in the future? Regarding the future trend of the traditional Chinese medicine industry, Southwest Securities once analyzed and pointed out that the policies of the traditional Chinese medicine industry are constantly changing, and the immune properties of traditional Chinese medicine consumer products are highlight.
In terms of policy, in fact, the policy support for the TCM industry in promoting TCM innovation, TCM internationalization, TCM quality control and TCM medical services is increasi.
Since 2021, including "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics", "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Chinese and Western Medicine", and "Implementation Plan for the Dissemination of Traditional Chinese Medicine Culture" (2021-2025) " and many other favorable policies have been introduced to support the innovation and development of the traditional Chinese medicine indust.
In 2021, a total of 33 Class 1 new drugs will be approved for marketing, including 6 proprietary Chinese medicin.
The local centralized procurement of proprietary Chinese medicines is mainly based on traditional Chinese medicine injections, and traditional Chinese medicine consumer goods have consumption attribut.
Since 2021, the upstream Chinese medicinal materials have ushered in a price increase, and the downstream of traditional Chinese medicine consumer goods with brand effects has gradually completed the price increase due to technical barrie.
The market is doing we.
In addition, traditional Chinese medicine consumer products are mainly in the out-of-hospital market, and the centralized procurement in the in-hospital market has less impact, so it is relatively immune to medical insuran.
The industry believes that there is a big opportunity for the development of traditional Chinese medicine consumer goods, and the future performance is expected to explo.
In addition, compared with proprietary Chinese medicines, the industry generally believes that Chinese herbal decoction pieces and formula granules are less pressured by medical insurance to control costs and have growth potenti.
Among them, under the introduction of national standards for formula granules, the industry is gradually moving towards standardized operation, and the increase in cost will bring about an increase in terminal pric.
In recent years, the market size of traditional Chinese medicine formula granules has grown rapidly, from 15 billion yuan in 2015 to about 30 billion yuan in 202 The industry expects that with the removal of restrictions on the use of formula granules, the market size of traditional Chinese medicine formula granules will still rema.
Rapid grow.
In recent years, Chinese herbal decoction pieces have also maintained a growth trend against the background of consumption leve.
In 2021, Chinese herbal medicine decoction pieces will have a high growth trend, with a profit growth rate of 10
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
